Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-Mutated Acute Myeloid Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04062266
What this trial is testing

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Who this might be right for
Acute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic Disorder+3 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06667973
What this trial is testing

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaFLT3 Gene MutationAdult AML+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto 80
Testing effectiveness (Phase 2)Looking for participantsNCT06235801
What this trial is testing

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Testing effectiveness (Phase 2)UnknownNCT04015024
What this trial is testing

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Who this might be right for
Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 30
Not applicableApproved For MarketingNCT03070093
What this trial is testing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Study completedNCT03900949
What this trial is testing

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Uma Borate 21
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07755202
What this trial is testing

Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

Who this might be right for
Acute Myeloid LeukemiaAML With FLT3 Mutation
Florian Kuchenbauer 20
Not applicableUnknownNCT05596981
What this trial is testing

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 60
Not applicableUnknownNCT05383014
What this trial is testing

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid Leukemia
Assiut University 82
Testing effectiveness (Phase 2)Ended earlyNCT03735875
What this trial is testing

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Leukemia
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT03280030
What this trial is testing

Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 67
Large-scale testing (Phase 3)UnknownNCT03642236
What this trial is testing

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Who this might be right for
FLT3-ITD MutationAcute Myeloid LeukemiaBrutons Tyrosine Kinase
Nanfang Hospital, Southern Medical University 122
Large-scale testing (Phase 3)Study completedNCT03182244
What this trial is testing

ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
AML With FLT3 Mutation
Astellas Pharma Inc 276
Testing effectiveness (Phase 2)WithdrawnNCT04982354
What this trial is testing

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Guenther Koehne
Testing effectiveness (Phase 2)Ended earlyNCT05028751
What this trial is testing

Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Kronos Bio 24
Not applicableNo Longer AvailableNCT05219266
What this trial is testing

Managed Access Programs for PKC412, Midostaurin

Who this might be right for
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaAggressive Systemic Mastocytosis+2 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01760655
What this trial is testing

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsAcute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM+18 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 62
Not applicableNo Longer AvailableNCT02624570
What this trial is testing

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML) WithFLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Novartis Pharmaceuticals
Next Page